Published in Blood Weekly, December 6th, 2001
For the third quarter of 2001, Vitex reported a net loss of $2.7 million, or $0.12 per share, compared with a net loss of $5.0 million or $0.25 per share, for the third quarter of 2000. Net revenues for the third quarter of 2001 were $5.2 million compared with $9.4 million for the third quarter of 2000.
On August 14, 2001, Vitex completed the divestiture of its plasma operations to Precision Pharma Services. The plasma operations accounted...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.